Alkermes (ALKS) PT Raised to $70 at Jefferies

Jefferies analyst Biren Amin reiterated a Buy rating an lifted his price target on Alkermes (NASDAQ: ALKS) to $70.00 (from $62.00) after ALKS 5461 for MDD at 2mg/2mg hit stat sig on MADRS-6 scale in FORWARD-5, the third of three PIII studies to assess efficacy of 5461.

Amin commented, "Mgmt has not released detailed analysis of the data yet but plans to at an upcoming medical meeting. Next steps are to meet with the FDA and the company plans to request that meeting soon. On its success we add 5461 revs into our model however assume a 50% risk discount which assumes regulatory risk, and we increase our PT to $70."

For an analyst ratings summary and ratings history on Alkermes click here. For more ratings news on Alkermes click here.

Shares of Alkermes closed at $43.51 yesterday.

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS